Merck is also developing a subcutaneous formulation of Keytruda that can extend its patent life. Merck is working on different strategies to drive Keytruda's long-term growth.Merck has been making meaningful regulatory and pipeline progress across areas like oncology, vaccines and infectious diseases while executing strategic business moves. Merck's phase III pipeline has almost tripled since 2021, supported by in-house pipeline progress as well as the addition of candidates through M&A deals.Merck's new products, Capvaxive and Winrevair, are witnessing strong launches and have the potential to generate significant revenues over the long term. Merck's long-acting monoclonal antibody, Enflonsia (clesrovimab), for the prevention of respiratory syncytial virus, was approved by the FDA last month.Merck recently intensified its acquisition strategy, actively pursuing deals to enhance its pipeline and diversify away from Keytruda.